A new clinical trial aims to investigate the use of virtual reality (VR) gamma sensory stimulation devices to alleviate fatigue in individuals living with multiple sclerosis (MS). The trial, sponsored by Clarity Health Technologies, Inc. in collaboration with Parc de Salut Mar, marks significant steps towards understanding how innovative medical devices can target the challenging symptom of fatigue faced by MS patients. This study is not yet recruiting, but clinical, regulatory, and quality teams should monitor its progress closely for potential implications in the medical device landscape.
Why is this trial significant?
Fatigue is one of the most pervasive and debilitating symptoms experienced by individuals with multiple sclerosis. Addressing this symptom using non-invasive, patient-centric methods is a critical unmet need. Virtual reality offers a unique opportunity to deliver targeted gamma sensory stimulation in a controlled environment. Gamma sensory stimulation refers to techniques used to activate gamma brain rhythms, which are believed to play a role in maintaining cognitive and neurological health.
This trial’s focus on VR technology signifies the growing interest in exploring digital therapeutics as adjunctive treatments. If successful, it could pave the way for broader applications of VR innovations in neurological diseases.
What are the devices being tested?
The trial will assess two types of devices:
- Virtual Reality Gamma Sensory Stimulation: This device is designed to deliver gamma stimulation through a virtual reality platform, targeting specific brain rhythms.
- Virtual Reality Sham Sensory Stimulation: As a control, this device mimics the visual and sensory aspects of gamma stimulation without delivering the therapeutic effect, ensuring the trial’s outcomes are scientifically robust.
These devices are intended to be user-friendly and non-invasive, emphasizing safety and patient comfort. Details about the technical specifications and protocols will likely emerge as the study progresses.
What is the current status and next steps?
As of January 12, 2026, the trial is listed as not yet recruiting. Researchers will begin the enrollment process once site selection and ethical approvals are finalized. Clinicians and manufacturers should pay close attention to study milestones, as the findings could influence future device development and regulatory approvals.
The trial is registered on ClinicalTrials.gov, offering transparency and accessibility to all stakeholders. For professionals, this ensures clear visibility into the study’s design, methodology, and eventual outcomes.
Frequently Asked Questions
- Who is conducting the trial?
The study is sponsored by Clarity Health Technologies, Inc. with contributions from Parc de Salut Mar. - What is the trial’s intended purpose?
To understand whether VR gamma stimulation can reduce fatigue in people with multiple sclerosis. - How does gamma stimulation work?
Gamma stimulation involves targeting gamma brain waves, which are linked to cognitive function and energy levels. - When does the trial begin?
The trial is “not yet recruiting” as of now. The enrollment start date will depend on site readiness and regulatory approvals. - Is this technology cleared by regulators?
Since this is an investigational study, the devices being tested are not yet cleared or approved for market use.
Conclusion
The upcoming trial marks another step forward in integrating virtual reality technology into clinical treatments. Regulatory and clinical professionals should watch its development, as the findings may influence therapeutic strategies for managing MS symptoms. With its focus on fatigue—a debilitating symptom for many MS patients—the study has the potential to make a meaningful impact on patient care.
Disclaimer
This content is intended for clinical, regulatory, and quality professionals. It is not legal or medical advice. For specific guidance, consult a qualified expert.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07310862?term=medical+device